Passage Bio terminates research collaboration and pays $2.3M to exit office lease
PASG sits 40% above its 52-week low of $3.935.
Summary
Passage Bio terminated a research collaboration agreement and paid a $2.3 million fee to exit an office lease, continuing its strategic restructuring to conserve cash amidst a going concern warning.
Key Events · Financing and Capital Events · PASG
-
Research Collaboration Terminated
Passage Bio terminated its research, collaboration, and license agreement with Gemma Biotherapeutics, Inc., which covered preclinical work for Huntington's disease and a paused program in Temporal Lobe Epilepsy.
-
Office Lease Terminated with $2.3M Fee
The company entered into a termination agreement for its 37,000 square foot office lease at 2005 Market Street, agreeing to pay a $2.3 million termination fee. This lease was originally set to expire in December 2031, and the company had already subleased most of the space.
-
Continuation of Restructuring
These terminations are part of Passage Bio's ongoing restructuring efforts, following a recent 75% workforce reduction and a going concern warning, aimed at conserving cash and reducing operational liabilities.
Analysis · PASG · Life Sciences
Passage Bio continues its restructuring efforts by terminating a research collaboration with Gemma Biotherapeutics and paying a $2.3 million fee to exit an office lease. This $2.3 million cash outflow is substantial for a company with a market capitalization of approximately $17.7 million, representing a significant immediate impact on its cash reserves. These actions, following a recent going concern warning and a 75% workforce reduction, underscore the company's critical need to conserve cash and reduce future liabilities, further signaling a significant contraction of its operations and pipeline.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 37.4% of the 3468 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASG was trading at $5.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.7M. The 52-week trading range was $3.94 to $20.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.